NAD+ and GLP-1 maintenance: what the research actually shows

A recent TikTok from Mariah Hopkins captures a relatable moment for many in the GLP-1 community: she loves her NAD+ routine but wishes it didn’t require daily commitment. The clip’s caption—“why can’t it be 1 day a week?!”—frames NAD+ as a maintenance tool alongside GLP-1 therapy. But what does the research actually say about NAD+ dosing frequency and its role in metabolic health?

What the clip is claiming

The video implies that NAD+ is an essential daily supplement for those on GLP-1 medications, and that its benefits are significant enough to warrant a daily ritual. The humor suggests a love-hate relationship with the frequency, not with the compound itself. The underlying message: NAD+ is a non-negotiable part of her maintenance protocol.

What the research neighborhood actually covers

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism, DNA repair, and sirtuin activation. Research in animal models and early human trials has explored NAD+ precursors (like NMN and NR) for age-related decline, mitochondrial function, and metabolic health. Some studies suggest that boosting NAD+ may improve insulin sensitivity and energy metabolism, which could theoretically complement GLP-1-based weight management. However, most human data are short-term and focus on precursors, not NAD+ itself.

Limits, missing context, and what a 15-second clip cannot show

The clip omits several critical points. First, NAD+ is not a GLP-1 receptor agonist; it does not mimic the appetite-suppressing or incretin effects of drugs like semaglutide or tirzepatide. Second, the optimal dosing frequency for NAD+ is not established. While some protocols use daily administration, others use cyclical or weekly regimens—there is no consensus. Third, the clip does not address potential side effects, interactions, or the fact that NAD+ research is still in early stages for metabolic indications. A 15-second video cannot convey the nuance of clinical evidence or individual variability.

How this maps to named research compounds

For researchers exploring NAD+ in the context of GLP-1 maintenance, the catalog includes NAD+ as a research-use peptide. It is often studied alongside other metabolic modulators like AOD9604 (Fragment 176-191), which is investigated for lipolysis, or Tesamorelin, which targets visceral fat. However, the clip specifically references NAD+, so we focus on that. NAD+ is available as a research compound, but its role in human maintenance protocols is not FDA-approved and remains experimental.

Research-use caveat

All compounds mentioned are for research use only, not for human consumption. This content is for informational purposes and does not constitute medical advice. Always consult a qualified professional for any health-related decisions.

Open the full video fact-check page (transcript, takeaways, embedded clip).